Anti-Vaccinia Virus 抗体 (ab35219)
Key features and details
- Rabbit polyclonal to Vaccinia Virus
- Suitable for: ELISA, IHC-Fr, WB, IHC-P, ICC/IF
- Reacts with: Vaccinia virus
- Isotype: IgG
製品の概要
-
製品名
Anti-Vaccinia Virus antibody
Vaccinia Virus 一次抗体 製品一覧 -
製品の詳細
Rabbit polyclonal to Vaccinia Virus -
由来種
Rabbit -
特異性
This antibody reacts with purified Virions. It does not react with uninfected cells. -
アプリケーション
適用あり: ELISA, IHC-Fr, WB, IHC-P, ICC/IFmore details -
種交差性
交差種: Vaccinia virus -
免疫原
Tissue, cells or virus corresponding to Vaccinia Virus. Vaccinia virus, New York City Board of Health (NYCBOH) strain.
-
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
バッファー
pH: 7.40
Preservative: 0.1% Sodium azide
Constituent: PBS -
Concentration information loading...
-
精製度
Protein A purified -
特記事項(精製)
This antibody is greater than 95% pure. -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
Compatible Secondaries
-
Isotype control
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab35219の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
ELISA |
1/500 - 1/2000.
|
|
IHC-Fr |
Use at an assay dependent concentration.
|
|
WB | (1) |
Use at an assay dependent concentration. Predicted molecular weight: 14 kDa. PubMed: 25093734
|
IHC-P | (2) |
Use at an assay dependent concentration. PubMed: 25093734
|
ICC/IF | (1) |
Use at an assay dependent concentration. PubMed: 22615950
|
特記事項 |
---|
ELISA
1/500 - 1/2000. |
IHC-Fr
Use at an assay dependent concentration. |
WB
Use at an assay dependent concentration. Predicted molecular weight: 14 kDa. PubMed: 25093734 |
IHC-P
Use at an assay dependent concentration. PubMed: 25093734 |
ICC/IF
Use at an assay dependent concentration. PubMed: 22615950 |
ターゲット情報
-
関連性
Vaccinia virus is an Orthopoxvirus, containing double stranded DNA. Fusion protein plays an important role in the entry of enveloped virus into cells. As vaccinia virus has a wide host range, it is conceivable that certain cellular components that are ubiquitously expressed on the cell mediate virus infection. The study of the entry process, attachment, fusion and the proteins and receptors involved is complex. During vaccinia virus infection, the fusion process is attributed to the action of the 14KDa protein (A27L). The N terminus of this protein recognises heparan sulfate on the cell surface. It interacts with the negative charges of sulfates of glycosaminoglycans (GAGs). Therefore, antibodies that recognize this 14KDa protein are able to neutralize vaccinia virus infection and enable identification other viral and cellular proteins which participate in the vaccinia virus entry process. -
別名
- Orthopoxvirus antibody
プロトコール
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (33)
ab35219 は 33 報の論文で使用されています。
- Ottolino-Perry K et al. Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis. Mol Ther Oncolytics 29:44-58 (2023). PubMed: 37180034
- Rodríguez-Cuadrado FJ et al. Clinical, histopathologic, immunohistochemical, and electron microscopic findings in cutaneous monkeypox: A multicenter retrospective case series in Spain. J Am Acad Dermatol 88:856-863 (2023). PubMed: 36581043
- Lee N et al. Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies. J Immunother Cancer 11:N/A (2023). PubMed: 36717184
- Koch J et al. Establishing a New Platform to Investigate the Efficacy of Oncolytic Virotherapy in a Human Ex Vivo Peritoneal Carcinomatosis Model. Viruses 15:N/A (2023). PubMed: 36851574
- Yang A et al. Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases. Mol Ther Oncolytics 31:100734 (2023). PubMed: 37915757